"We've still got the best universities, we've got some of the best scientists in the world, but it's not a good place to do the development work for medicines. It's an expensive place to operate, and it's a terrible place to sell medicines."
"There needs to be a proper plan from Treasury, sat down with the other departments, for what raising the spend to be more in line with other countries looks like."
A senior pharmaceuticals executive warned that Britain is becoming an unattractive location to develop and sell new medicines due to high operating costs and inadequate funding. Major firms have reduced clinical trials and moved research elsewhere, with one drugmaker cancelling a £1bn London research centre and another transferring laboratory work to the US. Sanofi invests modestly in UK R&D and has cut clinical trial activity by about half in recent years despite a strong drug pipeline. Plans to expand UK trials are paused pending tangible, cross‑department Treasury-led measures to boost life‑sciences competitiveness. NHS medicines spending has fallen to 9% of healthcare outlay.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]